As of June 1, Cedrik Britten is CMO at Immatics Biotechnologies – he joins after having previously worked as head of oncology cell therapy research at GSK.
The appointment fits neatly into Immatics’ work to discover and develop T cell redirecting cancer immunotherapies. Britten will be responsible for the management and development of the biotech’s clinical pipeline.
Immatics currently has eight programs in its pipeline, with four going through Phase I trials for solid and hematological cancers. Earlier this year, Britten’s former company actually partnered with Immatics to develop T-cell receptor therapies (TCR-Ts), as part of a potential $600m deal.
In Britten’s position at GSK, he had previously worked on the development of TCR-Ts and early-stage CAR-T programs.
The agreement to bring Britten onboard has also resulted in Stephen Eck, Immatics’ former CMO, stepping down from his position, though he will stay on to support the transition of Britten into the role.